Does combination therapy with abciximab reduce angiographically evident thrombus compared to thrombolytic monotherapy in patients with acute myocardial infarction?
Patients with acute myocardial infarction (AMI)
Combination therapy with abciximab
Thrombolytic monotherapy
Angiographically evident thrombus (AET)surrogate
Combination therapy with abciximab reduces angiographically evident thrombus and improves perfusion markers in acute myocardial infarction compared to thrombolytic monotherapy.
Compared with thrombolytic monotherapy, combination therapy with abciximab reduces AET, which in turn is associated with reduced residual stenosis and improved ST-segment resolution in AMI. These data provide a pathophysiological link between platelet inhibition, reduced thrombus, and improvements in both epicardial and microvascular perfusion in AMI.
Building similarity graph...
Analyzing shared references across papers
Loading...
C. Michael Gibson
James A. de Lemos
Sabina A. Murphy
Circulation
The University of Texas Southwestern Medical Center
Sabin Vaccine Institute
Baim Institute for Clinical Research
Building similarity graph...
Analyzing shared references across papers
Loading...
Gibson et al. (Tue,) studied this question.
www.synapsesocial.com/papers/69d56dd375589c71d767d0f8 — DOI: https://doi.org/10.1161/01.cir.103.21.2550